Market Overview:
The global Crohn's disease drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Crohn's disease, rising awareness about Crohn's disease and its treatment options, and technological advancements in the field of drug discovery and development. The global Crohn's disease drugs market is segmented on the basis of type into anti-inflammatory drugs, immune system suppressors, antibiotics, and others. The anti-inflammatory drug segment is expected to account for the largest share of the globalCrohn'sdisease drugs market in 2018. This segment is projected to grow at a CAGR of 6% duringthe forecast period from2018to2030. .
Product Definition:
Crohn's disease drugs are medications used to treat Crohn's disease, a type of inflammatory bowel disease. These drugs can help reduce inflammation in the digestive system, which can lead to relief from symptoms.
Anti-Inflammatory:
Anti-inflammatory drugs are used to reduce the inflammation caused by certain diseases. Inflammation is the body's natural response to injury or infection. The most common symptoms of inflammatory conditions are pain, redness, swelling and heat in one or more areas of the body.
Immune system suppressors:
Immune system suppressors are a new class of drugs that target the cause of Crohn's disease rather than the symptoms. They work by decreasing or eliminating immune response to normal gut bacteria which in turn reduces inflammation and pain caused by Crohn's disease.immune system suppressors have been tested to reduce inflammation in patients withcrohn's disease as well as healthy people, unlike other drugs which only affect those who already have IBD (inflammatory bowel disease).
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and hospital pharmacies, and other applications. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities along with a large patient base. In addition, presence of key players such as Teva Pharmaceuticals USA; Novartis; Pfizer; and Biogen Inc.; coupled with growing awareness about Crohn¢â‚¬â„¢s disease among patients is expected to drive growth over the forecast period.
The clinics/hospital pharmacies segment is anticipated to witness lucrative growth during the forecast period due to increasing prevalence of Inflammatory Bowel Disease (IBD) coupled with rising awareness about treatment options available for this condition. Moreover, expansion of specialty hospitals offering specialized care for IBD patients will further boost demand for these drugs in near future.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors driving the regional market. According to IMS Health, an analytics company that tracks pharmaceutical sales globally, in 2016 U.S.-based drug companies spent around USD X billion on R&D for Crohn’s disease drugs while worldwide they invested around USD X billion in cancer drugs during the same year.
Asia Pacific is expected to be one of fastest growing regions over the forecast period owing to rising healthcare expenditure and prevalence of chronic diseases such as ulcerative colitis.
Growth Factors:
- Increasing incidence of Crohn's disease
- Growing awareness about the disease
- Rising demand for better treatment options
- Technological advancements in drug delivery systems
- Availability of government funding for research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Crohn’s Disease Drugs Market Research Report
By Type
Anti-Inflammatory, Immune system suppressors, Antibiotics, Others
By Application
Hospitals, Clinics, Hospitalshospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Bayer AG, Amgen, Takeda Pharmaceutical, AbbVie, UCB, Ferring, Eli Lilly, Hoffman-La Roche, Bristol-Myers Squibb, Pfizer, Bayer AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Crohn’s Disease Drugs Market Report Segments:
The global Crohn’s Disease Drugs market is segmented on the basis of:
Types
Anti-Inflammatory, Immune system suppressors, Antibiotics, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Hospitalshospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- Amgen
- Takeda Pharmaceutical
- AbbVie
- UCB
- Ferring
- Eli Lilly
- Hoffman-La Roche
- Bristol-Myers Squibb
- Pfizer
- Bayer AG
Highlights of The Crohn’s Disease Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-Inflammatory
- Immune system suppressors
- Antibiotics
- Others
- By Application:
- Hospitals
- Clinics
- Hospitalshospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Crohn’s Disease Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Crohnu00c3u00a2u00e2u201au00acu00e2u201eu00a2s disease drugs are medications used to treat Crohnu00c3u00a2u00e2u201au00acu00e2u201eu00a2s disease. These medications can help improve the symptoms of Crohnu00c3u00a2u00e2u201au00acu00e2u201eu00a2s disease, such as pain, inflammation, and diarrhea.
Some of the key players operating in the crohn¢â‚¬â„¢s disease drugs market are Bayer AG, Amgen, Takeda Pharmaceutical, AbbVie, UCB, Ferring, Eli Lilly, Hoffman-La Roche, Bristol-Myers Squibb, Pfizer, Bayer AG.
The crohnƒ¢¢€š¬¢€¢s disease drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Crohn’s Disease Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Crohn’s Disease Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Crohn’s Disease Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Crohn’s Disease Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Crohn’s Disease Drugs Market Size & Forecast, 2018-2028
4.5.1 Crohn’s Disease Drugs Market Size and Y-o-Y Growth
4.5.2 Crohn’s Disease Drugs Market Absolute $ Opportunity
Chapter 5 Global Crohn’s Disease Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Crohn’s Disease Drugs Market Size Forecast by Type
5.2.1 Anti-Inflammatory
5.2.2 Immune system suppressors
5.2.3 Antibiotics
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Crohn’s Disease Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Crohn’s Disease Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Hospitalshospital Pharmacies
6.2.4 Retail Pharmacies
6.2.5 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Crohn’s Disease Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Crohn’s Disease Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Crohn’s Disease Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Crohn’s Disease Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Crohn’s Disease Drugs Market Size Forecast by Type
9.6.1 Anti-Inflammatory
9.6.2 Immune system suppressors
9.6.3 Antibiotics
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Crohn’s Disease Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Hospitalshospital Pharmacies
9.10.4 Retail Pharmacies
9.10.5 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Crohn’s Disease Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Crohn’s Disease Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Crohn’s Disease Drugs Market Size Forecast by Type
10.6.1 Anti-Inflammatory
10.6.2 Immune system suppressors
10.6.3 Antibiotics
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Crohn’s Disease Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Hospitalshospital Pharmacies
10.10.4 Retail Pharmacies
10.10.5 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Crohn’s Disease Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Crohn’s Disease Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Crohn’s Disease Drugs Market Size Forecast by Type
11.6.1 Anti-Inflammatory
11.6.2 Immune system suppressors
11.6.3 Antibiotics
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Crohn’s Disease Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Hospitalshospital Pharmacies
11.10.4 Retail Pharmacies
11.10.5 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Crohn’s Disease Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Crohn’s Disease Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Crohn’s Disease Drugs Market Size Forecast by Type
12.6.1 Anti-Inflammatory
12.6.2 Immune system suppressors
12.6.3 Antibiotics
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Crohn’s Disease Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Hospitalshospital Pharmacies
12.10.4 Retail Pharmacies
12.10.5 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Crohn’s Disease Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Crohn’s Disease Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Crohn’s Disease Drugs Market Size Forecast by Type
13.6.1 Anti-Inflammatory
13.6.2 Immune system suppressors
13.6.3 Antibiotics
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Crohn’s Disease Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Hospitalshospital Pharmacies
13.10.4 Retail Pharmacies
13.10.5 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Crohn’s Disease Drugs Market: Competitive Dashboard
14.2 Global Crohn’s Disease Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer AG
14.3.2 Amgen
14.3.3 Takeda Pharmaceutical
14.3.4 AbbVie
14.3.5 UCB
14.3.6 Ferring
14.3.7 Eli Lilly
14.3.8 Hoffman-La Roche
14.3.9 Bristol-Myers Squibb
14.3.10 Pfizer
14.3.11 Bayer AG
